Protara Therapeutics Reports Positive Phase 2 Data for Bladder Cancer Treatment TARA-002

Protara Therapeutics (Nasdaq: TARA) announced positive interim Phase 2 results for its cell-based therapy, TARA-002, targeting high-risk bladder cancer. The clinical data demonstrated a 68% complete response rate at the six-month mark for patients who were previously unresponsive to standard BCG therapy. Crucially, the trial reported no Grade 3 or higher treatment-related adverse events, highlighting a favorable safety profile for the experimental drug. These results stem from the ongoing ADVANCED-2 clinical trial, which focuses on a difficult-to-treat patient population. The company expects to complete patient enrollment for the current trial cohort by the second half of 2026. This strong efficacy and safety data are seen as significant catalysts for the biotech firm's clinical development path.